BeOne Medicines Ltd. American Depositary Shares(ONC)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ONC
$326.77
—
Snapshot
$326.77
Pre-market
$330.24
+1.06%
- 52-Week Range
- $253.95 – $385.22
- YTD
- +5.06%
- IV Rank (30D)
- 17.62
- Straddle Price
- $33.60
- P/C Vol Ratio
- 2.06
- Market Cap
- $33.2B
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.60% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 10.10% (VRP-adj) |
| WACC | 4.75% |
| Volatility Risk Premium | +31.3pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.7% |
| Rev. Growth (YoY, DCF input) | +15.1% |
| DCF Horizon | 12 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $1.1B |
| Return on Equity (TTM) | 10.8% |
| Gross Margin (TTM) | 88.3% |
| FCF Margin (TTM) | 18.4% |
| Debt / Equity | 0.20 |
| Quality Score | 5/6 — high quality (12y DCF) |
| SMA 50 | $291.63 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $300.89 |
| Bollinger Width / SMA20 | 5.9% (drives anchor stability) |
| Net Debt | $-3.8B |
Peers used for multiples: AMGN, GILD, MRNA, NTRA, REGN, RVMD, UTHR, VRTX
Model Conviction
47%
20-Day Fair Value
≈ by Aug 21, 2026
$347.71
α +6.4%
rank 49%
40-Day Fair Value
≈ by Sep 21, 2026
$336.14
α +2.9%
rank 32%
60-Day Fair Value
≈ by Oct 20, 2026
$345.43
α +5.7%
rank 30%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $7.52 | 13% | median 20.7× · 5 peers |
| Peer EV/EBITDA | n/a | 0% | median 16.7× · 5 peers |
| Peer P/B | n/a | 0% | median 6.6× · 8 peers |
| Peer P/S | n/a | 0% | median 8.4× · 7 peers |
| Market Anchor (SMA50) | $291.63 | 87% | stability 100% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-07-23 · updated
Info
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $33.2B
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +17.50% | 2 |
| Feb | +3.88% | 2 |
| Mar | +1.80% | 2 |
| Apr | -5.51% | 2 |
| May | -3.50% | 2 |
| Jun | -0.91% | 2 |
| Jul | +17.45% | 2 |
| Aug | +3.44% | 1 |
| Sep | +3.24% | 1 |
| Oct | -9.54% | 1 |
| Nov | +9.65% | 1 |
| Dec | -9.94% | 1 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $303.37
SMA 50: $291.95
SMA 200: $314.38
Current: $326.77
EMA 12: $311.72
EMA 26: $302.18
MACD: 9.5397 | Signal: 2.1504
BULLISH
ADX (14): 28.81
TREND
+DI: 34.19
−DI: 14.74
Momentum Oscillators
RSI (14): 70.53
OVERBOUGHT
Stoch %K: 84.84
Stoch %D: 79.21
Williams %R: -10.48
Volume & Volatility
BB Upper: $330.19
BB Lower: $276.55
NEUTRAL
OBV: 10,356,186
Vol SMA 20: 386,002
Vol ROC: 307.30%
ATR: $9.66
True Range: $13.32
HV 20: 28.6%
HV 30: 27.2%
HV 60: 31.5%
Data Summary
Data Points: 389
Last Updated:
Date Range: 2025-01-02T00:00:00 – 2026-07-23T00:00:00
AI Analysis
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
Earnings History
5 of 5 under expected move
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2025-05-07 | Pre-Market | 7.90% | 4.17% | 0.53x | Within |
| 2025-08-06 | Pre-Market | 7.54% | 2.83% | 0.38x | Within |
| 2025-11-06 | After-Close | 9.00% | 3.73% | 0.41x | Within |
| 2026-02-26 | Pre-Market | 10.05% | 8.60% | 0.86x | Within |
| 2026-05-06 | Pre-Market | 7.14% | 5.53% | 0.77x | Within |
Options Activity
- IV Rank (30D)
- 17.62
- IV Rank (7D)
- 17.62
- Avg IV
- 50.2%
- Straddle (30D)
- $33.60
- Straddle (7D)
- $33.60
- P/C Volume
- 2.06
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 0.73
- Correlation (SPY)
- 23.3%
- R²
- 0.05
- Ann. Volatility
- 39.8%
- SPY Volatility
- 12.7%
Low volatility - stock moves less than market
Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-06-30
? 13F Guide
Diluted shares outstanding: 1,482,971,250 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
7 filers$30.94M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $12.59M | 40.69% | 2026-03-31 |
| 2 | JANE STREET GROUP, LLC Custodian | $4.51M | 14.59% | 2026-03-31 |
| 3 | CITIGROUP INC Custodian | $4.16M | 13.44% | 2026-03-31 |
| 4 | CITADEL ADVISORS LLC Custodian | $3.56M | 11.52% | 2026-03-31 |
| 5 | BARCLAYS PLC Custodian | $3.12M | 10.08% | 2026-03-31 |
| 6 | Caption Management, LLC | $2.97M | 9.60% | 2026-03-31 |
| 7 | Walleye Capital LLC | $29.70K | 0.10% | 2026-03-31 |
8 filers$41.34M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $18.53M | 44.82% | 2026-03-31 |
| 2 | BARCLAYS PLC Custodian | $9.03M | 21.84% | 2026-03-31 |
| 3 | JANE STREET GROUP, LLC Custodian | $5.46M | 13.22% | 2026-03-31 |
| 4 | CITIGROUP INC Custodian | $4.16M | 10.06% | 2026-03-31 |
| 5 | CITADEL ADVISORS LLC Custodian | $2.44M | 5.89% | 2026-03-31 |
| 6 | WOLVERINE TRADING, LLC Custodian | $1.16M | 2.82% | 2025-09-30 |
| 7 | D. E. Shaw & Co., Inc. Custodian | $475.15K | 1.15% | 2026-03-31 |
| 8 | Walleye Capital LLC | $89.09K | 0.22% | 2026-03-31 |
Insider Activity
Latest: 2026-07-22
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-07-22 | JOHN OYLER | Chief Executive Officer | Mixed | −75,723 | $269.08 | -$30.51M | EDGAR |
| 2026-07-17 | JOHN OYLER | Chief Executive Officer | Mixed | — | $215.98 | -$12.41M | EDGAR |
| 2026-07-17 | JOHN OYLER | Chief Executive Officer | Mixed | — | $230.42 | -$48.21M | EDGAR |
| 2026-07-14 | JOHN OYLER | Chief Executive Officer | Mixed | −12,261 | $185.53 | -$37.40M | EDGAR |
| 2026-07-14 | JOHN OYLER | Chief Executive Officer | Mixed | — | $170.04 | -$16.03M | EDGAR |
| 2026-07-10 | Chan Henry Lee | SVP, General Counsel | Mixed | — | $247.01 | -$73.6K | EDGAR |
| 2026-06-25 | Xiaobin Wu | President and COO | Sell (S) | −1,292 | $276.26 | -$356.9K | EDGAR |
| 2026-06-25 | Lai Wang | President, Global Head of R&D | Sell (S) | −1,068 | $276.74 | -$295.6K | EDGAR |
| 2026-06-25 | JOHN OYLER | Chief Executive Officer | Sell (S) | −3,410 | $273.78 | -$933.6K | EDGAR |
| 2026-06-18 | Xiaobin Wu | President and COO | Sell (S) | −1,357 | $266.76 | -$362.0K | EDGAR |
| 2026-06-18 | Chan Henry Lee | SVP, General Counsel | Sell (S) | −590 | $265.98 | -$156.9K | EDGAR |
| 2026-06-18 | JOHN OYLER | Chief Executive Officer | Sell (S) | −3,693 | $265.55 | -$980.7K | EDGAR |
| 2026-06-18 | Lai Wang | President, Global Head of R&D | Sell (S) | −1,169 | $265.39 | -$310.2K | EDGAR |
| 2026-06-15 | OLIVIER BRANDICOURT | Director | Award (A) | +18,980 | — | EDGAR | |
| 2026-06-15 | Alessandro Riva | Director | Award (A) | +18,980 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
18 insiders · @ $326.77
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Xiaodong Wang | Director | 8,635,593 | $2.82B | -$60.76M | 12 | 2026-06-15 |
| 2 | FELIX BAKER | Director | 730,643 | $238.75M | -$1.14B | 1 | 2025-02-28 |
| 3 | 667, L.P. | Director | 730,643 | $238.75M | -$1.57M | 2 | 2026-05-27 |
| 4 | Lai Wang | President, Global Head of R&D | 601,965 | $196.70M | -$6.77M | 15 | 2026-06-25 |
| 5 | JULIAN BAKER | Director | 161,551 | $52.79M | $0 | 1 | 2026-06-15 |
| 6 | JOHN OYLER | Chief Executive Officer | 148,206 | $48.43M | -$320.65M | 23 | 2026-07-22 |
| 7 | Titus B. Ball | Principal Accounting Officer | 99,645 | $32.56M | -$154.9K | 4 | 2026-06-15 |
| 8 | ANTHONY C HOOPER | Director | 83,720 | $27.36M | $0 | 2 | 2026-06-15 |
| 9 | Alessandro Riva | Director | 73,164 | $23.91M | -$65.6K | 3 | 2026-06-15 |
| 10 | Margaret Dugan | Director | 73,164 | $23.91M | -$65.6K | 3 | 2026-06-15 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/E Ratio | 990.2 |
| P/B Ratio | 7.0 |
| P/S Ratio | 5.8 |
| EV/EBITDA | 35.3 |
| TTM Revenue | $5.7B |
| TTM Net Income | $0.5B |
| TTM EPS | $0.33 |
| ROE | 10.8% |
| Debt/Equity | 0.23 |